Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene*

  title={Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene*},
  author={Carlo Iavarone and Mario Acunzo and Francesca Carlomagno and Annunziata Catania and Rosa Marina Melillo and Stella M Carlomagno and Massimo Santoro and Mario Chiariello},
  journal={Journal of Biological Chemistry},
  pages={10567 - 10576}
Mitogen-activated protein (MAP) kinases have a central role in several biological functions, including cell adhesion and spreading, chemotaxis, cell cycle progression, differentiation, and apoptosis. Extracellular signal-regulated kinase 8 (Erk8) is a large MAP kinase whose activity is controlled by serum and the c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate Erk8, and we demonstrate that such MAP kinase… 

Figures from this paper

XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway

Downregulation of XB130 in TPC1 papillary thyroid cancer cells, harboring the RET/PTC1 kinase, strongly reduced Akt activity without altering ERK1/2 phosphorylation, and concomitantly inhibited cell-cycle progression and survival in suspension.

Extracellular Signal-regulated Kinase 8 (ERK8) Controls Estrogen-related Receptor α (ERRα) Cellular Localization and Inhibits Its Transcriptional Activity*

It is demonstrated that ERK8 is able to counteract, in immortalized human mammary cells, ERRα activation induced by the EGF receptor pathway, often deregulated in breast cancer.

Extracellular signal-regulated kinase 8-mediated NF-κB activation increases sensitivity of human lung cancer cells to arsenic trioxide

It is reported that ERK8 is highly expressed in several human lung cancer cell lines and is positively correlated with their sensitivities to the anti-cancer drug arsenic trioxide (As2O3), suggesting for the first time a regulatory paradigm of NF-κB activation by ERK9 upon As2O2 treatment in human lung cancers; and a potential therapeutic advantage of As2 O3 that might gain more selective killing of cancer cells with high ERK7 expression.

Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer.

It is found that ERK8 is relatively highly expressed in HCT15 human colorectal cancer cells and plays an important role in the promotion and progression of coloreCTal cancer.

Identification of Functionally Distinct TRAF Proinflammatory and Phosphatidylinositol 3-Kinase/Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (PI3K/MEK) Transforming Activities Emanating from RET/PTC Fusion Oncoprotein*

Functional uncoupling of the two pathways demonstrates that intrinsic pro-inflammatory pathways are not required for cellular transformation and suggests a need for further investigation into the role inflammation plays in thyroid tumor progression.

Regulation of human mitogen‐activated protein kinase 15 (extracellular signal‐regulated kinase 7/8) and its functions: A recent update

It remains unclear whether MAPK15 acts as a proto‐oncogene or tumor suppressor, but examinations of the role ofMAPK15 in various cell lines and model systems indicate that it participates in a variety of cellular activities.

In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice

This review focuses on the current status of MAP kinase knock-in and knock-out mouse models and their phenotypes, and examples of the application ofMAP kinase transgenic mice for validating therapeutic properties of specific MAP kinases inhibitors, and for investigating the role of MAP Kinase in pathogen-host interactions will be discussed.

Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1*

Evidence is provided of a direct link between IDO1 expression and the oncogenic activation of RET in thyroid carcinoma and the involved signal transduction pathways are described to suggest possible novel molecular targets for the abrogation of tumor microenvironment immunosuppression.

The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions.

Four MAPK cascades have been identified in the last 20 years and those are usually named according to the MAPK components that are the central building blocks of each of the cascades, and the existence of several distinct components in each tier of the different cascades is described.



Regulation of c-myc expression by PDGF through Rho GTPases

It is shown that PDGF enhances c-myc expression and stimulates the c- myc promoter in a Src-dependent manner, and that neither Ras nor the mitogen-activated protein kinase pathway mediate these effects.

A Network of Mitogen-Activated Protein Kinases Links G Protein-Coupled Receptors to the c-jun Promoter: a Role for c-Jun NH2-Terminal Kinase, p38s, and Extracellular Signal-Regulated Kinase 5

Evidence is obtained that GPCRs can potently stimulate the activity of the c-jun promoter through MEF2 transcription factors, which do not act downstream from JNK, and that the activation of certain kinases acting downstream from MEK5 (ERK5) and MKK6 (p38α and p38γ) is necessary to fully activate the c.jun promoter.

Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret

It is shown that triggering the endogenous Ret, expressed in PC12 cells, induces JNK activity and Ret is able to activate JNK either when transiently transfected in COS-1 cells or when stably expressed in NIH3T3 fibroblasts or in PC Cl 3 epithelial thyroid cells.

ERK8, a New Member of the Mitogen-activated Protein Kinase Family*

Although most closely related to ERK7, the relatively low sequence identity, minimal basal activity, and different substrate profile identify ERK8 as a distinct member of the MAPK family that is activated by an Src-dependent signaling pathway.

Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade

It is demonstrated that FRS2 couples both ligand-regulated and oncogenic forms of RET, with the MAP kinase signaling cascade as part of the response of RET under normal biological conditions and pathological conditions, such as MEN 2 and papillary thyroid carcinomas.

Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.

The results demonstrate that the involvement of Bcr/Abl in the p38 MAPK pathway is a key mechanism for explaining resistance to Ara-C, and could provide a clue for new therapeutic approaches based on the use of specific Abl inhibitors.

ERK7 Is an Autoactivated Member of the MAPK Family*

Results indicate that autophosphorylation is sufficient for ERK7 activation and that the C-terminal domain regulates its kinase activity through multiple interactions.

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF.

It is reported that a membrane pool of c-Abl is activated by the growth factors PDGF and EGF in fibroblasts, and it is shown for the first time that c- Abl functions in the cellular response to growth factors.

The Unique C-terminal Tail of the Mitogen-activated Protein Kinase ERK5 Regulates Its Activation and Nuclear Shuttling*

Results indicate that ERK5 signaling is directed by the presence of its unique C-terminal tail, which might be the key to understanding the key role of ERk5 in MAPK signaling.

Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor

It is suggested that the RAS and PI3-K pathways activated by GDNF bifurcate mainly through SHC bound to tyrosine 1062 in RET, which is important for activation of CREB and NF-κB in GDNF-treated cells, respectively.